Session

Back to Programme Overview

Management of recurrence after local treatment

Poster Session 72

  • Location:
    Room Paris, North Hall (Level 1)
  • Chairs:
     S. Joniau, Leuven (BE)
     N. Mottet, Saint-Étienne (FR)
     K. Touijer, New York (US)
  • Aims and objectives of this session

    To evaluate the imaging and markers for recurrence and adjuvant or salvage treatments results.

  • Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.
950
External validation of a TCP model predicting PSA relapse after post-prostatectomy radiotherapy

By: Broggi S.2, Galla A.3, Saracino B.4, Faiella A.4, Fossati N.5, Gabriele D.3, Maggio A.3, Sanguineti G.4, Di Muzio N.1, Briganti A.1, Cozzarini C.1, Fiorino C.2

Institutes: 1San Raffaele Scientific Institute, Dept. of Radiotherapy, Milan, Italy, 2San Raffaele Scientific Institute, Dept. of Medical Physics, Milan, Italy, 3Candiolo Cancer Institute – FPO, IRCCS, Dept. of Radiotherapy, Candiolo, Italy, 4Regina Elena National Cancer Institute, Dept. of Radiotherapy, Rome, Italy, 5San Raffaele Scientific Institute, Dept. of Urology, Milan, Italy

951
Genomic classifier augments the role of pathological features in identifying optimal candidates for adjuvant radiation therapy in patients with prostate cancer: Development and internal validation of a multivariable prognostic model

By: Dalela D.1, Santiago-Jimenez M.2, Yousefi K.2, Karnes J.3, Ross A.4, Den R.5, Freedland S.6, Schaeffer E.7, Dicker A.5, Menon M.1, Briganti A.8, Abdollah F.1

Institutes: 1Henry Ford Health System, Vattikuti Urology Institute, Detroit, United States of America, 2GenomeDx Biosciences, GenomeDx Biosciences, Vancouver, Canada, 3Mayo Clinic, Dept. of Urology, Rochester, United States of America, 4Johns Hopkins Hospital, James Buchanan Brady Urological Institute, Baltimore, United States of America, 5Sidney Kimmel Cancer Center, Thomas Jefferson University, Dept. of Radiation Oncology, Philadelphia, United States of America, 6Samuel Oschin Comprehensive Cancer Center, Cedars-Sinai Medical Center, Dept. of Surgery, Division of Urology, Los Angeles, United States of America, 7Northwestern University, Feinberg School of Medicine, Dept. of Urology, Chicago, United States of America, 8Vita Salute San Raffaele Hospital, Dept. of Urology, Milan, Italy

952
Natural history of patients treated with salvage radiation therapy for rising PSA after radical prostatectomy: A long-term survival analysis

By: Briganti A.1, Fossati N.1, Karnes J.2, Boorjian S.2, Colicchia M.2, Bossi A.3, Cozzarini C.4, Fiorino C.4, Noris Chiorda B.4, Dell’Oglio P.1, Gandaglia G.1, Wiegel T.5, Shariat S.6, Goldner G.7, Joniau S.8, Battaglia A.8, Haustermans K.9, De Meerleer G.9, Fonteyne V.10, Ost P.10, Van Poppel H.5, Montorsi F.1

Institutes: 1Vita-Salute University San Raffaele, Dept. of Urology, Milan, Italy, 2Mayo Clinic, Dept. of Urology, Rochester, United States of America, 3Gustave Roussy Institute, Dept. of Radiation Oncology, Villejuif, France, 4Vita-Salute University San Raffaele, Dept. of Radiotherapy, Milan, Italy, 5University Hospital Ulm, Dept. of Radiation Oncology, Ulm, Germany, 6Medical University of Vienna, Dept. of Urology, Vienna, Austria, 7Medical University of Vienna, Dept. of Radiation Oncology, Vienna, Austria, 8University Hospitals Leuven, Dept. of Urology, Leuven, Belgium, 9University Hospitals Leuven, Dept. of Radiotherapy, Leuven, Belgium, 10Ghent University Hospital, Dept. of Radiotherapy, Ghent, Belgium

* 953
Identifying the optimal candidate for salvage lymph node dissection for nodal recurrence of prostate cancer: Results from a large, multi-institutional analysis

By: Suardi N.1, Briganti A.1, Fossati N.1, Dell’Oglio P.1, Gandaglia G.1, Colicchia M.2, Karnes J.R.2, Haidl F.8, Pfister D.8, Porres D.8, Heidenreich A.8, Gratzke C.7, Herlemann A.7, Stief C.7, Battaglia A.5, Everaerts W.5, Joniau S.5, Van Poppel H.5, Aksenov A.4, Osmonov D.K.4, Jünemann K.P.9, Abreu A.D.L.3, Almeida F.3, Fay C.6, Gill I.6, Mottrie A.M.10, Montorsi F.1

Institutes: 1Vita-Salute University San Raffaele, Dept. of Urology, Milan, Italy, 2Mayo Clinic, Dept. of Urology, Rochester, Minnesota, United States of America, 3Phoenix Imaging Center, Dept. of Urology, Phoenix, Arizona, United States of America, 4Department of Urology and Pediatric Urology, University Hospital Schleswig Holstein, Campus Kiel, Dept. of Urology, Kiel, Germany, 5University Hospitals Leuven, Urology, Dept of Development and Regeneration, Leuven, Belgium, 6Keck School of Medicine, University of Southern California, USC Institute of Urology, Catherine & Joseph Aresty Department of Urology, Los Angeles, California, United States of America, 7Ludwig-Maximilians-University, Dept. of Urology, Munich, Germany, 8University of Cologne, Dept. of Urology, Cologne, Germany, 9University Hospital Schleswig Holstein, Campus Kiel, Dept. of Urology and Pediatric Urology, Kiel, Germany, 10OLV Ziekenhuis Aalst, Belgium ORSI Academy, Dept. of Urology, Melle, Belgium

954
Selection criteria for surveillance in patients with biochemical recurrence after radical prostatectomy

By: Mikami H., Numao N., Yamamoto S., Hagiwara K., Uehara S., Takeda H., Inoue T., Ogawa M., Yuasa T., Masuda H., Fukui I., Yonese J.

Institutes: Cancer Institute Hospital, Japanese Foundation for Cancer Research, Dept. of Urology, Koto-Ku, Japan

955
Adjuvant versus early salvage radiation therapy in node positive prostate cancer patients: A long-term survival analysis

By: Fossati N.1, Karnes R.J.2, Boorjian S.2, Colicchia M.2, Bossi A.3, Cozzarini C.4, Fiorino C.4, Chiorda B.N.4, Gandaglia G.1, Dell’Oglio P.1, Wiegel T.5, Shariat S.6, Goldner G.7, Joniau S.8, Battaglia A.8, Haustermans K.9, De Meerleer G.9, Fonteyne V.10, Ost P.10, Van Poppel H.5, Montorsi F.1, Briganti A.1

Institutes: 1Vita-Salute University San Raffaele, Dept. of Urology, Milan, Italy, 2Mayo Clinic, Dept. of Urology, Rochester, United States of America, 3Gustave Roussy Institute, Dept. of Radiation Oncology, Villejuif, France, 4Vita-Salute University San Raffaele, Dept. of Radiotherapy, Milan, Italy, 5University Hospital Ulm, Dept. of Radiation Oncology, Ulm, Germany, 6Medical University of Vienna, Dept. of Urology, Vienna, Austria, 7Medical University of Vienna, Dept. of Radiation Oncology, Vienna, Austria, 8University Hospitals Leuven, Dept. of Urology, Leuven, Belgium, 9University Hospitals Leuven, Dept. of Radiotherapy, Leuven, Belgium, 10Ghent University Hospital, Dept. of Radiotherapy, Ghent, Belgium

956
Salvage external beam radiation therapy (EBRT) for local recurrence after high intensity focused ultrasound (HIFU) failure versus salvage HIFU for local recurrence after EBRT failure: A long term analysis

By: Lee J-W.1, Crouzet S.1, Soria J.1, Chapelon A.2, Chapelon J.Y.2, Melodelima C.3, Gal J.4, Pasticier G.5, Mege-Lechevallier F.6, Rouvière O.7, Gelet A.1

Institutes: 1Hospices Civils De Lyon, Dept. of Urology and Transplantation, Lyon, France, 2Inserm, U1032, LabTau, Lyon, France, 3Laboratoire d’Ecologie Alpine, , Grenoble, France, 4Centre Antoine Lacassagne, Dept. of Biostatistics, Nice, France, 5Pellegrin Hospital, Dept. of Urology and Transplantation, Bordeaux, France, 6Edouard Herriot Hospital, Dept. of Pathology, Lyon, France, 7Edouard Herriot Hospital, Dept. of Radiology, Lyon, France

957
Predictive factors of positive 68Ga-PSMA PET/CT in patients with PSA recurrence following radical prostatectomy

By: Tosco L.1, Joniau S.1, Witters M.1, Battaglia A.1, Cromphout L.2, Goffin K.2, Gheysens O.2, Deroose C.2, Oyen R.2, Van Laere K.2

Institutes: 1Uz Leuven – Campus Gasthuisberg, Dept. of Urology, Leuven, Belgium, 2Uz Leuven – Campus Gasthuisberg, Dept. of Nuclear Imaging, Leuven, Belgium

958
Clinical impact of 68Ga-PSMA PET/CT in prostate cancer patients with rising PSA after treatment with curative intent: Preliminary analysis of a multidisciplinary approach

By: Albisinni S.1, Artigas C.2, Aoun F.1, Biaou I.1, Gil T.3, Hawaux E.1, Limani K.1, Otte F.X.4, Peltier A.1, Sideris S.3, Sirtaine N.5, Flamen P.2, Van Velthoven R.1

Institutes: 1Institut Jules Bordet, Dept. of Urology, Brussels, Belgium, 2Institut Jules Bordet, Dept. of Nuclear Medicine, Brussels, Belgium, 3Institut Jules Bordet, Dept. of Oncology, Brussels, Belgium, 4Institut Jules Bordet, Dept. of Radiotherapy, Brussels, Belgium, 5Institut Jules Bordet, Dept. of Pathology, Brussels, Belgium

959
68Ga-PSMA PET/CT improves biochemical response after salvage lymph node dissection for nodal recurrence in prostate cancer patients

By: Herlemann A.1, Kretschmer A.1, Buchner A.1, Karl A.1, Tritschler S.1, El-Malazi L.1, Wenter V.2, Ilhan H.2, Bartenstein P.2, Stief C.1, Gratzke C.1

Institutes: 1Ludwig-Maximilians-University Munich, Dept. of Urology, Munich, Germany, 2Ludwig-Maximilians-University Munich, Dept. of Nuclear Medicine, Munich, Germany

960
The comparison of prognoses between radiotherapy and radical prostatectomy in patients with high risk localized or locally advanced prostate cancer treated with neoadjuvant hormonal therapy

By: Joung J.Y.1, Kim S.H.1, Seo H.K.1, Chung J.1, Cho K.H.2, Park W.S.3, Lee K.H.1

Institutes: 1National Cancer Center, Dept. of Genitourinary Cancer Branch, Goyang, South Korea, 2National Cancer Center, Proton Therapy Center, Dept. of Radiation Oncology, Goyang, South Korea, 3National Cancer Center, Dept. of Pathology, Goyang, South Korea

962
Stereotactic radiotherapy for bone and nodal oligometastases: Patterns of relapse in a prospective clinical trial

By: Siva S.2, Udovicich C.1, Shaw M.2, Violet J.2, Chander S.2, Bressel M.3, Goad J.1, Lawrentschuck N.1, Foroudi F.1, Murphy D.1

Institutes: 1Peter Maccallum Cancer Centre, Dept. of Urology, Melbourne, Australia, 2Peter Maccallum Cancer Centre, Dept. of Radiation Oncology, Melbourne, Australia, 3Peter Maccallum Cancer Centre, Dept. of Biostatistics and Clinical Trials, Melbourne, Australia

963
Assessing the risk of early and late toxicity of post-prostatectomy radiation therapy: A long-term multi-institutional analysis

By: Briganti A.1, Fossati N.5, Karnes J.2, Boorjian S.2, Colicchia M.2, Bossi A.3, Cozzarini C.4, Fiorino C.4, Noris Chiorda B.4, Dell’Oglio P.5, Gandaglia G.5, Wiegel T.6, Shariat S.7, Goldner G.8, Joniau S.9, Battaglia A.9, Haustermans K.10, De Meerleer G.10, Fonteyne V.11, Ost P.11, Van Poppel H.9, Montorsi F.5

Institutes: 1Vita-Salute University San Raffaele, Dept. of Urology, Milan, Italy, 2Mayo Clinic, Dept. of Urology, Rochester, United States of America, 3Gustave Roussy Institute, Dept. of Urology, Villejuif, France, 4Vita-Salute University San Raffaele, Dept. of Radiotherapy, Milan, Italy, 5Vita-Salute University San Raffaele, Dept. of Oncology and Urology, Milan, Italy, 6University Hospital Ulm, Dept. of Radiation Oncology, Ulm, Germany, 7Medical University of Vienna, Dept. of Oncology and Urology, Vienna, Austria, 8Medical University of Vienna, Dept. of Radiation Oncology, Vienna, Austria, 9University Hospitals Leuven, Dept. of Urology, Leuven, Belgium, 10University Hospitals Leuven, Dept. of Radiotherapy, Leuven, Belgium, 11Ghent University Hospital, Dept. of Radiotherapy, Ghent, Belgium